Eli Lilly, the manufacturer of Mounjaro (tirzepatide), offers a savings card program for eligible participants. Other resources may also be available to help you save on the cost of your Mounjaro ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...

The US Navy’s beleaguered shipbuilding program took a major hit on Tuesday as Navy Secretary John Phelan announced he was cancelling plans to buy Constellation-class frigates, once heralded as a key ...

The Navy is walking away from the Constellation-class frigate program to focus on new classes of warships the service can build faster, Secretary of the Navy John Phelan announced Tuesday on social ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

WASHINGTON — As part of next steps for the Janus Program, the Department of the Army has selected nine installations for consideration in which to site microreactor power plants, and the Defense ...

When I first wrote “Vector databases: Shiny object syndrome and the case of a missing unicorn” in March 2024, the industry was awash in hype. Vector databases were positioned as the next big thing — a ...

DayZ and Kerbal Space Program's creators have joined forces with an ex-SpaceX engineer to create the ultimate spaceflight simulator. When you purchase through links on our site, we may earn an ...

As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech declaring Novo's offer "superior"—even though it has already inked an ...